Activation of PDE2 and PDE5 by specific GAF ligands: Delayed activation of PDE5

British Journal of Pharmacology

Volumn 161, Issue 7, 2010, Pages 1645-1660

  Jäger, Ronald ^a   Schwede, Frank ^b   Genieser, Hans Gottfried ^b   Koesling, Doris ^a   Russwurm, Michael ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b BIOLOG Life Science Institute   (Germany)

Author keywords

Cyclic guanosine monophosphate; Cyclic nucleotide analogues; GAF domains; Phosphodiesterase 2; Phosphodiesterase 5; Phosphodiesterases

Indexed keywords

5, 6 DICHLOROBENZIMIDAZOLE RIBOSIDE 3', 5' CYCLIC MONOPHOSPHATE; 5, 6 DIMETHYLBENZIMIDAZOLE RIBOSIDE 3', 5' CYCLIC MONOPHOSPHATE; 8 BROMO CYCLIC GMP; CYCLIC GMP; GUANOSINE DERIVATIVE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE V; UNCLASSIFIED DRUG;

ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CONCENTRATION RESPONSE; ENZYME ACTIVATION; ENZYME KINETICS; ENZYME PHOSPHORYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEK293 CELLS; HUMANS; LIGANDS; MICE; NATRIURETIC PEPTIDES; NITRIC OXIDE; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 78149373626     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00977.x     Document Type: Article

References (42)

1. Alexander SP, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC). 4th edn. Br J Pharmacol 158: S1-S254.
2. Aravind L, Ponting CP (1997). The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22: 458-459.
3. Beavo JA, Hardman JG, Sutherland EW (1971). Stimulation of adenosine 3', 5'-monophosphate hydrolysis by guanosine 3', 5'-monophosphate. J Biol Chem 246: 3841-3846.
4. Bender AT, Beavo JA (2006). Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58: 488-520.
5. Cheng Y, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
6. Corbin JD, Turko IV, Beasley A, Francis SH (2000). Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267: 2760-2767.
7. Corbin JD, Blount MA, Weeks JL 2nd, Beasley A, Kuhn KP, Ho YS et al. (2003). [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63: 1364-1372.
8. Erneux C, Couchie D, Dumont JE, Baraniak J, Stec WJ, Abbad EG et al. (1981). Specificity of cyclic GMP activation of a multi-substrate cyclic nucleotide phosphodiesterase from rat liver. Eur J Biochem 115: 503-510.
9. Francis SH, Lincoln TM, Corbin JD (1980). Characterization of a novel cGMP binding protein from rat lung. J Biol Chem 255: 620-626.
10. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ et al. (2002). Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity. J Biol Chem 277: 47581-47587.
11. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D (1998). YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54: 962-967.
12. Frieden C (1979). Slow transitions and hysteretic behavior in enzymes. Annu Rev Biochem 48: 471-489.
13. Frieden C (2008). A lifetime of kinetics. J Biol Chem 283: 19873-19878.
14. Genieser HG, Winkler E, Butt E, Zorn M, Schulz S, Iwitzki F et al. (1992). Derivatives of 1-beta-D-ribofuranosylbenzimidazole 3', 5'-phosphate that mimic the actions of adenosine 3', 5'-phosphate (cAMP) and guanosine 3', 5'-phosphate (cGMP). Carbohydr Res 234: 217-235.
15. Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE (2006). cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281: 2841-2846.
16. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, Trong HL, Colbran JL et al. (1993). The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 268: 22863-22873.
17. Manganiello VC, Tanaka T, Murashima S (1990). Cyclic GMP-stimulated cyclic nucleotide phosphodiesterases. In: Beavo J, Houslay MD (eds). Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action. John Wiley and Sons Ltd: New York, pp. 61-85.
18. Martinez SE, Wu AY, Glavas NA, Tang XB, Turley S, Hol WG et al. (2002). The two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP binding. Proc Natl Acad Sci USA 99: 13260-13265.
19. Miot F, Van Haastert PJ, Erneux C (1985). Specificity of cGMP binding to a purified cGMP-stimulated phosphodiesterase from bovine adrenal tissue. Eur J Biochem 149: 59-65.
20. Mo E, Amin H, Bianco IH, Garthwaite J (2004). Kinetics of a cellular nitric oxide/cGMP/phosphodiesterase-5 pathway. J Biol Chem 279: 26149-26158.
21. Moss J, Manganiello VC, Vaughan M (1977). Substrate and effector specificity of a guanosine 3':5'-monophosphate phosphodiesterase from rat liver. J Biol Chem 252: 5211-5215.
22. Mullershausen F, Russwurm M, Thompson WJ, Liu L, Koesling D, Friebe A (2001). Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 155: 271-278.
23. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003). Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160: 719-727.
24. Mullershausen F, Russwurm M, Koesling D, Friebe A (2004). In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation. Mol Biol Cell 15: 4023-4030.
25. Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS (2009). Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci USA 106: 18225-18230.
26. Poppe H, Rybalkin SD, Rehmann H, Hinds TR, Tang XB, Christensen AE et al. (2008). Cyclic nucleotide analogs as probes of signaling pathways. Nat Methods 5: 277-278.
27. Russell TR, Terasaki WL, Appleman MM (1973). Separate phosphodiesterases for the hydrolysis of cyclic adenosine 3', 5'-monophosphate and cyclic guanosine 3', 5'-monophosphate in rat liver. J Biol Chem 248: 1334-1340.
28. Russwurm M, Mullershausen F, Friebe A, Jager R, Russwurm C, Koesling D (2007). Design of fluorescence resonance energy transfer (FRET)-based cGMP indicators: a systematic approach. Biochem J 407: 69-77.
29. Russwurm C, Zoidl G, Koesling D, Russwurm M (2009). Dual acylation of PDE2A splice variant 3: targeting to synaptic membranes. J Biol Chem 284: 25782-25790.
30. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA (2002). Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem 277: 3310-3317.
31. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003). PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22: 469-478.
32. Rybalkina IG, Tang XB, Rybalkin SD (2010). Multiple affinity states of cGMP-specific phosphodiesterase for sildenafil inhibition defined by cGMP-dependent and cGMP-independent mechanisms. Mol Pharmacol 77: 670-677.
33. Stroop SD, Beavo JA (1991). Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem 266: 23802-23809.
34. Thomas MK, Francis SH, Corbin JD (1990). Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265: 14971-14978.
35. Turko IV, Haik TL, McAllister-Lucas LM, Burns F, Francis SH, Corbin JD (1996). Identification of key amino acids in a conserved cGMP-binding site of cGMP-binding phosphodiesterases. A putative NKXnD motif for cGMP binding. J Biol Chem 271: 22240-22244.
36. Turko IV, Francis SH, Corbin JD (1998). Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. Biochem J 329: 505-510.
37. Turko IV, Ballard SA, Francis SH, Corbin JD (1999). Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 56: 124-130.
38. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH et al. (2006). Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281: 21469-21479.
39. Wu AY, Tang XB, Martinez SE, Ikeda K, Beavo JA (2004). Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 279: 37928-37938.
40. Wyatt TA, Naftilan AJ, Francis SH, Corbin JD (1998). ANF elicits phosphorylation of the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol 274: H448-H455.
41. Yamamoto T, Manganiello VC, Vaughan M (1983). Purification and characterization of cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from calf liver. Effects of divalent cations on activity. J Biol Chem 258: 12526-12533.
42. Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005). Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280: 12051-12063.